Incidence and diagnosis of active toxoplasma infection among liver transplant recipients in Western Turkey

Ayşe Caner, Mert Döşkaya, Zeki Karasu, Aysu Değirmenci, Edward Guy, Murat Kılıç, Murat Zeytunlu, Janet Francis, Ata Bozoklar, Yüksel Gürüz – 29 September 2008 – Toxoplasmosis is a serious and potentially life‐threatening disease in liver transplant recipients while they are immunosuppressed. We report the clinical and laboratory findings related to active toxoplasma infection associated with 40 immunosuppressed liver transplant procedures that took place over a 12‐month period at a major transplant unit in Izmir, Turkey.

Auxiliary transplantation for acute liver failure: Histopathological study of native liver regeneration

Alberto Quaglia, Bernard C. Portmann, Alex S. Knisely, Parthi Srinivasan, Paolo Muiesan, Julia Wendon, Michael A. Heneghan, John G. O'Grady, Marianne Samyn, Dino Hadzic, Anil Dhawan, Giorgina Mieli‐Vergani, Nigel Heaton, Mohamed Rela – 29 September 2008 – Auxiliary liver transplantation (ALT) permits the serial assessment of regeneration in livers of patients with acute liver failure (ALF). Forty‐nine ALF patients [32 adults (median age, 23 years; range, 16‐40 years) and 17 children (median age, 12 years; range, 1‐15 years)] underwent ALT between 1994 and 2004 at King's College Hospital.

Risk factors and outcomes in post–liver transplantation bile duct stones and casts: A case‐control study

Bret J. Spier, Patrick R. Pfau, Katelin R. Lorenze, Stuart J. Knechtle, Adnan Said – 29 September 2008 – Bile duct stones and casts (BDS) after liver transplantation are associated with significant morbidity. Risk factors for BDS formation and the efficacy of treatment in liver transplant recipients have not been systematically studied. The aim of this study was to evaluate potential risk factors for the formation of BDS in patients post–liver transplant.

High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation

Minna Ilmakunnas, Eija M. Tukiainen, Ari Rouhiainen, Heikki Rauvala, Johanna Arola, Arno Nordin, Heikki Mäkisalo, Krister Höckerstedt, Helena Isoniemi – 29 September 2008 – High mobility group box 1 protein (HMGB1), a cytokine actively secreted by phagocytes and passively released from necrotic cells, is an inflammatory mediator in experimental hepatic ischemia/reperfusion injury. We characterized its expression in human liver transplantation.

Subscribe to